Mirum Pharmaceuticals (MIRM) Enterprise Value (2018 - 2026)

Mirum Pharmaceuticals' Enterprise Value history runs 9 years deep, the most recent figure standing at -$386.3 million for Q1 2026.

• In Q1 2026, Enterprise Value fell 39.11% year-over-year to -$386.3 million; the TTM figure through Mar 2026 stood at -$386.3 million (down 39.11% YoY), while the FY2025 annual figure was -$383.3 million, down 36.54% from the prior year.
• Enterprise Value was -$386.3 million for Q1 2026 at Mirum Pharmaceuticals, down from -$383.3 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$125.0 million in Q2 2022 to a low of -$434.9 million in Q3 2022.
• Historically, Enterprise Value has averaged -$298.4 million across 5 years, with a median of -$302.8 million in 2024.
• Biggest YoY gain for Enterprise Value was 60.4% in 2023; the steepest drop was 164.06% in 2023.
• A 5-year view of Enterprise Value shows it stood at -$251.7 million in 2022, then retreated by 13.75% to -$286.3 million in 2023, then increased by 1.95% to -$280.7 million in 2024, then plunged by 36.54% to -$383.3 million in 2025, then slipped by 0.76% to -$386.3 million in 2026.
• The last three Enterprise Value figures came in at -$386.3 million (Q1 2026), -$383.3 million (Q4 2025), and -$375.5 million (Q3 2025), per Business Quant data.